Welcome to our dedicated page for Agile Therapeutics news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on Agile Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agile Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agile Therapeutics's position in the market.
Agile Therapeutics (Nasdaq: AGRX), a women's healthcare company, announced that its CEO, Al Altomari, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:20 p.m. ET. The event will be accessible via live webcast on the Investor Relations page of Agile Therapeutics' website and will be archived for 30 days. Agile Therapeutics focuses on contraceptive solutions, including its product Twirla, a non-daily prescription contraceptive.
Agile Therapeutics (AGRX) reported its first quarter 2021 financial results, showing promising growth in Twirla prescriptions, with 1,853 total scripts by March 31, 2021, driven by an expanding base of over 850 healthcare providers. The company achieved $116,000 in net revenue, though it faced a net loss of $17.1 million, or $0.20 per share. Operating expenses rose to $15.2 million, up from $7.6 million in the prior year. Despite challenges, Agile continues efforts to broaden Twirla's market access, including securing Medicaid coverage in multiple states.
Agile Therapeutics (Nasdaq: AGRX) announced that a post hoc analysis of the Phase 3 SECURE Trial for Twirla® will be presented at ACOG Annual Meeting from April 30 to May 2, 2021. This analysis evaluates safety and efficacy in women with BMI 25 kg/m
Summary not available.
Agile Therapeutics (Nasdaq: AGRX) will report its first quarter 2021 financial results on May 4, 2021, after market close. A live conference call is scheduled for 4:30 p.m. EDT. Investors can join by dialing (866) 324-3683 for domestic calls or (509) 844-0959 internationally. The webcast will be available via their Investor Relations page. Agile aims to meet women's healthcare needs with its non-daily contraceptive, Twirla, utilizing proprietary Skinfusion technology.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that Chairman and CEO Al Altomari will present at two upcoming investor conferences in March 2021. The events include the H.C. Wainwright Global Life Sciences Conference, available on-demand starting March 9, 2021, and the Oppenheimer 31st Annual Virtual Healthcare Conference on March 17, 2021. Webcasts of the presentations will be accessible on Agile's website for 30 days following each conference. Agile Therapeutics focuses on women's healthcare, offering innovative contraceptive options like their product Twirla®.
Agile Therapeutics, Inc. (AGRX) reported a net loss of $17.6 million for Q4 2020, with gross revenue exceeding $1 million following the launch of Twirla®. The company has secured $45 million in credit from Perceptive Advisors, enhancing financial flexibility. Agile achieved about 40-45% commercial formulary coverage for Twirla and expects further growth through agreements with wholesalers and Sterling Specialty Pharmacy. Despite increased sales, marketing, and R&D expenses, the firm is optimistic about its trajectory, supported by a new national awareness campaign.
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. ET the same day to discuss the results and provide a business update. The company offers innovative contraceptive solutions, including Twirla®, a non-daily prescription contraceptive patch. Investors can access the call via the company's Investor Relations page.
Agile Therapeutics (Nasdaq: AGRX) announced that its Chairman and CEO, Al Altomari, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The event will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern Time on the Investors section of Agile's website. An archived version will remain accessible for 30 days. Agile Therapeutics focuses on women's healthcare, with its initial product, Twirla, a non-daily prescription contraceptive patch, utilizing proprietary Skinfusion technology.
Agile Therapeutics, Inc. (Nasdaq: AGRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 9:10 a.m. ET. The conference will be held virtually, allowing broader access for participants.
A live webcast of the presentation will be available on Agile's Investor Relations page, and an archived version will remain accessible for 30 days. Agile focuses on women's healthcare and offers contraceptive solutions via its Twirla® transdermal system, allowing women flexibility in their contraceptive choices without the need for daily pills.